The
NEW ENGLAND
JOURNAL 0 MEDICINE
1.0
1
0.9
3
0.8
Hazard ratio, 0.51 (95% Cl,0.34-0.77)
1
0.7
P=0.001
0.6
]
0s
Placebo (N= 223)
5
0.3
0.2
[
Belimumab (N= 223)
0.0
16
24
32
40
48
56
64
72
80
88
96
104
Weeks
ORIGINAL ARTICLE
Two-Year Trial of Belimumab in
Lupus Nephritis
R. Furie and Others
This phase 3 multicenter; randomized, double-blind,
placebo-controlled 2-year trial compared the efficacy
and safetuofintravenous belimumakwith those of
THIS SITE
USES COOKIES to
personalize content; to
measure website
and
advertising performance, and to
present relevant advertising
By continuing to use our
you accept the use
of these cookies. To learn more, please visit our
Cookie Information page.
site ,